Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/15300
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huber, M | - |
dc.contributor.author | Präger, M | - |
dc.contributor.author | Coyle, K | - |
dc.contributor.author | Coyle, D | - |
dc.contributor.author | Lester-George, A | - |
dc.contributor.author | Trapero-Bertran, M | - |
dc.contributor.author | Nemeth, B | - |
dc.contributor.author | Cheung, KL | - |
dc.contributor.author | Stark, R | - |
dc.contributor.author | Vogl, M | - |
dc.contributor.author | Pokhrel, S | - |
dc.contributor.author | Leidl, R | - |
dc.date.accessioned | 2017-10-25T13:07:21Z | - |
dc.date.available | 2017-10-25T13:07:21Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Addiction,(2017) | en_US |
dc.identifier.issn | 0965-2140 | - |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/15300 | - |
dc.description.abstract | Aims: To evaluate costs, effects and cost effectiveness of increased reach of specific smoking cessation interventions in Germany. Design: A Markov-based state transition return on investment model (EQUIPTMOD) was used to evaluate current smoking cessation interventions as well as two prospective investment scenarios. A healthcare perspective (extended to include out-of-pocket payments) with lifetime horizon was considered. A probabilistic analysis was used to assess uncertainty around predicted estimates. Setting: Germany. Participants: Cohort of current smoking population (18+ years) in Germany. Interventions: Interventions included group-based behavioral support, financial incentive programs and varenicline. For Prospective Scenario 1 the reach of group-based behavioral support, financial incentive program and varenicline was increased by 1% of yearly quit attempts (=57,915 quit attempts), while Prospective Scenario 2 represented a higher reach mirroring the levels observed in England. Measurements: EQUIPTMOD considered reach, intervention cost, number of quitters, QALYs gained, cost effectiveness and return on investment. Findings: The highest returns through reduction in smoking-related healthcare costs were seen for the financial incentive program (€2.71 per €1 invested), followed by that of group-based behavioral support (€1.63 per €1 invested), compared with no interventions. Varenicline had lower returns (€1.02 per €1 invested) than the other two interventions. At the population level, Prospective Scenario 1 led to 15,034 QALYs gained and €27 million cost-savings, compared with Current Investment. Intervention effects and reach contributed most to the uncertainty around the return-on-investment estimates. At a hypothetical willingness-to-pay threshold of only €5,000, the probability of being cost effective is around 75% for Prospective Scenario 1. Conclusions Increasing the reach of group-based behavioral support, financial incentives and varenicline for smoking cessation by just 1% of current annual quit attempts provides a strategy to German policy makers that improves the population’s health outcomes and that may be considered cost-effective. | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY | en_US |
dc.subject | Smoking cessation | en_US |
dc.subject | Germany | en_US |
dc.subject | Cost effectiveness | en_US |
dc.subject | Behavioral support | en_US |
dc.subject | Pharmacotherapy | en_US |
dc.subject | Policy | en_US |
dc.subject | EQUIPTMOD | en_US |
dc.title | Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD | en_US |
dc.type | Article | en_US |
dc.relation.isPartOf | Addiction | - |
pubs.publication-status | Accepted | - |
Appears in Collections: | Dept of Health Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 575.96 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.